<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069389</url>
  </required_header>
  <id_info>
    <org_study_id>EDS_2020_HOPICOV</org_study_id>
    <nct_id>NCT05069389</nct_id>
  </id_info>
  <brief_title>Registry of Management Strategies for Patients With COVID-19 in Healthcare Establishments</brief_title>
  <acronym>HOPICOV</acronym>
  <official_title>Registry of Management Strategies for Patients With COVID-19 in Healthcare Establishments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Emile Roux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Médipôle Lyon-Villeurbanne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Saint-Lô</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Valence</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Troyes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Hospitalier La Rochelle Ré Aunis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier William Morey - Chalon sur Saône</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Saint-Malo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Intercommunal de Mont de Marsan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Intercommunal de Poissy / Saint-Germain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Dax</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Public du Cotentin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Henri Duffaut - Avignon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Boulogne sur Mer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Louis Pasteur, Chartres</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Montauban</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Saint-Brieuc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Hospitalier Aube Marne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Emile Roux</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to describe medical care strategies implemented by healthcare&#xD;
      establishments for patients affected by COVID-19&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronavirus infection (SARS-Cov2), very contagious, is benign in the most cases but can be&#xD;
      complicated by an acute respiratory distress syndrome, for which an invasive mechanical&#xD;
      ventilation in resuscitation is necessary with an important mortality rate. This infection is&#xD;
      about an important health crisis with a fast saturation of the health system.&#xD;
&#xD;
      In front of the novelty of this virus, any effective treatment has been demonstrated in&#xD;
      humans and researches have accelerated as this pandemic continues.&#xD;
&#xD;
      First available results, in chinese population, have not demonstrated superiority of the&#xD;
      Lopinavir/Ritonavir association versus standard care (Cao et al. 2020). In a randomized study&#xD;
      in 62 chinese patients, Chen et al. seems to find a clinical efficacy of the&#xD;
      Hydroxychloroquine compared to placebo. Gautret et al. has also found a decreased viral load&#xD;
      in nasopharyngeal swabs in patients affected by COVID-19, treated by Hydroxychloroquine and&#xD;
      by the association of Hydroxychloroquine-Azythromycine. However, these preliminary results&#xD;
      doesn't allow to conclue on the efficacy against COVID-19.&#xD;
&#xD;
      Currently, any treatment in particular is recommanded for patients affected by COVID-19.&#xD;
      Randomized studies on a larger scale and greater rigor at national and european level are in&#xD;
      process to determine the efficacy of several treatments.&#xD;
&#xD;
      Pending results of these studies, healthcare establishments had to adapt and strategize to&#xD;
      take care their patients. These strategies have rapidely evolved during this pandemy, in&#xD;
      terms of the therapeutic clinical studies opening, the acquisition of new knowledges on&#xD;
      COVID-19, and treatments.&#xD;
&#xD;
      Screening : All patients with a COVID-19 diagnosis who have been treated in 2020 in&#xD;
      participant establishements will be included in the HOPICOV study.&#xD;
&#xD;
      Enrolment : On discharge from hospital, an information notice will be delivered to the&#xD;
      patient (or at his close relative / his legal guardian) to allow him to exert his right to&#xD;
      oppose his collection data identified as part of the treatment. Otherwise, this information&#xD;
      might be send by letter after his discharge.&#xD;
&#xD;
      All participating centers will be encouraged to enter data as things progress to allow&#xD;
      interim analysis and scientific communication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Describe management strategies implemented by healthcare establishments for patients with covid-19, depending on the evolution of scientific knowledge and recommendations for specific treatments.</measure>
    <time_frame>During the hospitalization</time_frame>
    <description>The use of specific treatments or specific care in COVID unit, inclusion in clinical trials, will be combined to report the evolution of French recommendations and scientific literature around the COVID-19.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe management strategies to take care depending on the patient</measure>
    <time_frame>During the hospitalization</time_frame>
    <description>Specific and non specific administered treatments, inclusion in clinical trials, depending on the patients' age, symptoms at admission, comorbidities (including the presence of renal failure, unbalanced diabetes or heart disorder based on laboratory criteria and ECG) will be combined to describe different management strategies to take care depending on the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare patients' clinical course who received different management strategies</measure>
    <time_frame>During the hospitalization</time_frame>
    <description>Comparison of hospitalization time (days), time between the onset and the end of symptoms (days), passage in intensive care and patients' vital status, according to the treatments received (non-specific / standard versus the different specific treatments administered off-label within the framework of clinical trials or not) will be combined to compare the patients' clinical course who received different management strategies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the cost of the care</measure>
    <time_frame>During the hospitalization</time_frame>
    <description>Costs of specific treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of the care</measure>
    <time_frame>During the hospitalization</time_frame>
    <description>Hospitalization time and survival status will be combined to evaluate the effectiveness of the care</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2071</enrollment>
  <condition>COVID-19 Infection</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Some data will be collected for all patients included :&#xD;
specific treatment administered in COVID unit&#xD;
dosages of treatment&#xD;
inclusion in clinical trials&#xD;
Evolution of French recommendations and the publication of scientific articles</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patient diagnosed for COVID-19 infection and hospitalized in healthcare establishment&#xD;
        in 2020&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any adult patient admitted to the establishment for treatment for a SARS-Cov2&#xD;
             infection&#xD;
&#xD;
          -  Positive RT-PCR or a scanner suggestive of COVID-19 during the stay, or with a&#xD;
             positive serology (even if carried out after the patient's discharge)&#xD;
&#xD;
          -  Hospitalization &gt; 24h&#xD;
&#xD;
          -  Patients receiving any type of care, whether it is recommended standard care or&#xD;
             off-label treatment as part of a therapeutic clinical trial or outside the scope of&#xD;
             clinical research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opposition to the use of data following written patient information&#xD;
&#xD;
          -  Patient transferred from another hospital to continue COVID care and whose initial&#xD;
             care data is not available&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emilie GADEA-DESCHAMPS, PhD</last_name>
    <phone>+33 4 71 04 35 38</phone>
    <email>science.writer@ch-lepuy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Center Emile Roux</name>
      <address>
        <city>Le Puy-en-Velay</city>
        <zip>43012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie GADEA-DESCHAMPS, PhD</last_name>
      <phone>+33 (0)4 71 04 35 38</phone>
      <email>science.writer@ch-lepuy.fr</email>
    </contact>
    <investigator>
      <last_name>Benjamin CASTAGNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe LEROY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos EL KHOURY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>medical care strategies</keyword>
  <keyword>hospitalisation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

